Federal health agencies moved to suspend the rollout of Johnson & Johnson’s Covid-19 vaccine in the U.S. Tuesday following reports of “rare and severe” blood clotting in six recipients, recommending the vaccine’s rollout be put on hold as a precaution while the safety issues are investigated. 

Key Facts

The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) issued a joint statement Tuesday recommending the U.S. pause the use of Johnson & Johnson’s Covid-19 vaccine while the reports of rare blood clots are investigated. 

The agencies said they were making the recommendation out of an “abundance of caution,”  noting that there have been just six reported cases out of nearly 7 million doses administered. 

All cases occurred in women between the ages of 18 and 48, with symptoms occurring 6 to 13 days after vaccination.

An emergency meeting of the CDC’s advisory committee has been set for Wednesday, the statement said, and both agencies will evaluate the issue to determine whether the FDA should continue to authorize the vaccine. 

This is a developing story…

Full coverage and live updates on the Coronavirus